109 related articles for article (PubMed ID: 25198405)
1. Virologic and genetic evaluation of vemurafenib-induced skin cancers.
Dika E; Patrizi A; Altimari A; Fiorentino M; La Placa M; Gruppioni E; Venturoli S; Vaccari S; Melotti B; Piraccini BM; Fanti PA
Cutan Ocul Toxicol; 2015; 34(3):251-3. PubMed ID: 25198405
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
3. Eruptive squamous cell carcinomas after vemurafenib therapy.
Mays R; Curry J; Kim K; Tsai K; Arora A; Khan F; Ramirez-Fort M; Ciurea A
J Cutan Med Surg; 2013; 17(6):419-22. PubMed ID: 24138980
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
[TBL] [Abstract][Full Text] [Related]
5. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
Kent R; Glorioso S; Nordberg ML
J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
[TBL] [Abstract][Full Text] [Related]
6. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
7. Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
Sinha R; Larkin J; Fearfield L
Br J Dermatol; 2015 Apr; 172(4):1135-6. PubMed ID: 25234953
[No Abstract] [Full Text] [Related]
8. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Holderfield M; Lorenzana E; Weisburd B; Lomovasky L; Boussemart L; Lacroix L; Tomasic G; Favre M; Vagner S; Robert C; Ghoddusi M; Daniel D; Pryer N; McCormick F; Stuart D
Cancer Res; 2014 Apr; 74(8):2238-45. PubMed ID: 24523442
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma.
Alloo A; Garibyan L; LeBoeuf N; Lin G; Werchniak A; Hodi FS; Flaherty KT; Lawrence DP; Lin JY
Arch Dermatol; 2012 Mar; 148(3):363-6. PubMed ID: 22431777
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus evaluation of vemurafenib-induced skin epithelial tumors: a case series.
Dika E; Patrizi A; Venturoli S; Fanti PA; Barbieri D; Strammiello R; Melotti B; La Placa M
Br J Dermatol; 2015 Feb; 172(2):540-2. PubMed ID: 25041062
[No Abstract] [Full Text] [Related]
11. Vemurafenib-related cutaneous side effects ameliorated by acitretin.
Chon SY; Sambrano BL; Geddes ER
J Drugs Dermatol; 2014 May; 13(5):586-8. PubMed ID: 24809883
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
[TBL] [Abstract][Full Text] [Related]
13. Association of Vemurafenib and Pipobroman Enhances BRAF-CRAF Dimerization in Squamous Cell Carcinoma.
Cassius C; Pages C; Roux J; Lhote R; Lavocat R; Réa D; Bagot M; Mourah S; Battistella M; Lebbé C; Dumaz N
J Invest Dermatol; 2016 Jun; 136(6):1302-1305. PubMed ID: 26854489
[No Abstract] [Full Text] [Related]
14. Drug safety evaluation of vemurafenib in the treatment of melanoma.
Tsai KY; Nowroozi S; Kim KB
Expert Opin Drug Saf; 2013 Sep; 12(5):767-75. PubMed ID: 23800008
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
17. Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.
Herms F; Kramkimel N; Regnier-Rosencher E; Carlotti A; Chanal J; Boitier F; Aractingi S; Dupin N; Avril MF
Melanoma Res; 2016 Oct; 26(5):487-91. PubMed ID: 27261949
[TBL] [Abstract][Full Text] [Related]
18. Vitiligo of the Face in a Patient Treated With Vemurafenib for Metastatic Melanoma.
Nasca MR; Lacarrubba F; Ferraù F; Micali G
J Drugs Dermatol; 2016 Jun; 15(6):766-8. PubMed ID: 27272087
[TBL] [Abstract][Full Text] [Related]
19. [Vemurafenib-induced toxic epidermal necrolysis].
Wantz M; Spanoudi-Kitrimi I; Lasek A; Lebas D; Quinchon JF; Modiano P
Ann Dermatol Venereol; 2014 Mar; 141(3):215-8. PubMed ID: 24635957
[TBL] [Abstract][Full Text] [Related]
20. (18)F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib.
Nguyen BD
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):64-6. PubMed ID: 26251366
[No Abstract] [Full Text] [Related]
[Next] [New Search]
